Following regulatory guidelines, the participant's illness is being reviewed and monitored by an independent Data Safety Monitoring Board (DSMB) and the company's own internal clinical and safety physicians. The study pause is a standard component of the clinical trial protocol, and is different from a regulatory hold, according to the company.

The phase III Ensemble trial was initiated in September and aims to enroll over 60,000 individuals globally. With a study of this magnitude, the company noted that adverse events are an anticipated occurrence. The pause will allow it to review all relevant medical information to determine whether to restart the study.

J&J to supply EU with 200M COVID-19 vaccine doses
Johnson & Johnson has received approval from the European Commission to supply 200 million doses of Janssen Pharmaceutical's COVID-19 vaccine...

J&J completes $6.5B acquisition of Momenta
Johnson & Johnson has successfully completed its acquisition of Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion.

National Institutes of Health launches 4th phase III COVID-19 vaccine study
A phase III clinical trial evaluating the investigational Janssen COVID-19 vaccine Ad26.COV2.S for the prevention of symptomatic COVID-19 in a single-dose...

J&J to acquire Momenta for $6.5B
Johnson & Johnson has entered an agreement to acquire Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion with...

J&J to provide U.S. with 100M doses of COVID-19 vaccine
Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives...